Home › Research › Drug development
A novel therapeutic prospect: a dual-acting tirzepatide for Alzheimer's disease
Alshehri GH, Al-Kuraishy HM, Al-Gareeb AI, Fawzy MN, Waheed HJ, Papadakis M, Alexiou A, El-Saber Batiha G.. European journal of pharmacology, 2025-07-22
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease (AD), the leading cause of dementia, involves microglial activation, pro-inflammatory cytokine release, and impaired insulin signaling via insulin receptor substrate 1 (IRS-1) inhibition. Brain insulin resistance (BIR) is a key factor in AD progression, disrupting synaptic plasticity and neuronal function. Additionally, glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) signaling, which regulate insulin pathways, are compromised in AD. GLP-1/GIP receptor activation or their analogs, such as tirzepatide, show potential in mitigating AD neuropathology. However, the precise neuroprotective mechanisms of tirzepatide remain unclear. This mini-review explores tirzepatide's potential therapeutic effects in AD, focusing on its role in restoring insulin signaling, reducing neuroinflammation, and improving cognitive function. Understanding these mechanisms could offer new insights into AD treatment strategies.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Alshehri, G. H., Al-Kuraishy, H. M., Al-Gareeb, A. I., Fawzy, M. N., Waheed, H. J., Papadakis, M., et al. (2025). A novel therapeutic prospect: a dual-acting tirzepatide for Alzheimer's disease. European journal of pharmacology. https://doi.org/10.1016/j.ejphar.2025.177979
Vancouver
Alshehri GH, Al-Kuraishy HM, Al-Gareeb AI, Fawzy MN, Waheed HJ, Papadakis M, et al. A novel therapeutic prospect: a dual-acting tirzepatide for Alzheimer's disease. European journal of pharmacology. 2025. doi:10.1016/j.ejphar.2025.177979. PMID: 40706971.
BibTeX
@article{alshehri2025-40706971,
author = {Alshehri, G. H. and Al-Kuraishy, H. M. and Al-Gareeb, A. I. and Fawzy, M. N. and Waheed, H. J. and Papadakis, M. and Alexiou, A. and El-Saber Batiha, G.},
title = {{A novel therapeutic prospect: a dual-acting tirzepatide for Alzheimer's disease}},
journal = {European journal of pharmacology},
year = {2025},
doi = {10.1016/j.ejphar.2025.177979},
pmid = {40706971},
url = {https://doi.org/10.1016/j.ejphar.2025.177979}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Additionally, glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) signaling, which regulate insulin pathways, are compromised in AD.
- GLP-1/GIP receptor activation or their analogs, such as tirzepatide, show potential in mitigating AD neuropathology.
- However, the precise neuroprotective mechanisms of tirzepatide remain unclear.
- This mini-review explores tirzepatide's potential therapeutic effects in AD, focusing on its role in restoring insulin signaling, reducing neuroinflammation, and improving cognitive function.
- Understanding these mechanisms could offer new insights into AD treatment strategies.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 24 of the 58 points we could judge it on, which is 41 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (European journal of pharmacology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40706971) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 24 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 24 of the 58 points we could judge it on is 41 out of 100. |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development from nearby years
Also tagged “tirzepatide”
3 studies in the library carry the topic tag “tirzepatide”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 3 tagged studies.